Notably, orthotopic injection of a Kras/p53-mutated mouse PDAC cell line (KPC) into syngeneic WT mice allows the rapid development of pancreatic tumors with a severe metastatic burden that results in complete mortality within 3–5 weeks of implantation56, and administration of dFdC dramatically reduces tumor burden to delay mortality. The gene discussed is KRAS; the disease is pancreatic neoplasm.